Marker Therapeutics
MRKR
8 hedge funds and large institutions have $904K invested in Marker Therapeutics in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
199% more capital invested
Capital invested by funds: $302K → $904K (+$602K)
0.12% more ownership
Funds ownership: 0.1% → 0.22% (+0.12%)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NRS
Neville Rodie & Shaw
New York
|
+$375K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.1K |
| 3 |
BlackRock
New York
|
+$1.78K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$921 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
-$5.56K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NRS
1
Neville Rodie & Shaw
New York
| $479K | +$375K | +12,210 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $356K | +$26.1K | +850 | +10% |
|
|
3
BlackRock
New York
| $57K | +$1.78K | +58 | +4% |
|
|
4
UBS Group
Zurich,
Switzerland
| $9K | +$921 | +30 | +15% |
|
|
NSIM
5
North Star Investment Management
Chicago,
Illinois
| $2K | -$5.56K | -181 | -81% |
|
|
AG
6
Advisor Group
Phoenix,
Arizona
| $1K | – | – | – |
|
MRKR Hedge Fund Activity: Q4 2017 in Review
8 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2017, worth a combined $904K — up 199% from $302K a quarter earlier.
Fund positioning in MRKR was balanced in Q4 2017: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Neville Rodie & Shaw, opening a new position worth an estimated $375K. The largest seller was North Star Investment Management, cutting an estimated $5.56K.
- 8 institutional investors held Marker Therapeutics (MRKR) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $904K of Marker Therapeutics stock for Q4 2017, up 199% quarter-over-quarter.
- 1 fund opened new Marker Therapeutics positions in Q4 2017 and 1 closed out, a net change of 0 holders.
- The largest Marker Therapeutics buyer in Q4 2017 was Neville Rodie & Shaw, an estimated $375K added.
- The largest Marker Therapeutics seller in Q4 2017 was North Star Investment Management, an estimated $5.56K sold.
Based on aggregated 13F filings for Q4 2017.